Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Sep;43(9):932-960.
doi: 10.1007/s12272-020-01268-5. Epub 2020 Sep 9.

Repositioning medication for cardiovascular and cerebrovascular disease to delay the onset and prevent progression of Alzheimer's disease

Heeyoung Lee  1 , EunYoung Kim  2
Affiliations
Review

Repositioning medication for cardiovascular and cerebrovascular disease to delay the onset and prevent progression of Alzheimer's disease

Heeyoung Lee et al. Arch Pharm Res. 2020 Sep.

Abstract

Alzheimer's disease (AD) is a complex, progressive, neurodegenerative disorder. As with other common chronic diseases, multiple risk factors contribute to the onset and progression of AD. Many researchers have evaluated the epidemiologic and pathophysiological association between AD, cardiovascular diseases (CVDs), and cerebrovascular diseases (CBVDs), including commonly reported risk factors such as diabetes, hypertension, and dyslipidemia. Relevant therapies of CVDs/CBVDs for the attenuation of AD have also been empirically investigated. Considering the challenges of new drug development, in terms of cost and time, multifactorial approaches such as therapeutic repositioning of CVD/CBVD medication should be explored to delay the onset and progression of AD. Thus, in this review, we discuss our current understanding of the association between cardiovascular risk factors and AD, as revealed by clinical and non-clinical studies, as well as the therapeutic implications of CVD/CBVD medication that may attenuate AD. Furthermore, we discuss future directions by evaluating ongoing trials in the field.

Keywords: Alzheimer's disease; Cardiovascular disease; Cerebrovascular disease; Drug repositioning; Pharmacotherapeutic implications.

PubMed Disclaimer

References

    1. A novel therapeutic target for Alzheimer's disease in men and women 50–85 years of age. ClinicalTrials.gov. https://www.clinicaltrials.gov/ct2/show/NCT03752294?term=NCT03752294&amp... . Accessed 2 June 2020
    1. A trial of cilostazol in patients with mild cognitive impairment (COMCID). ClinicalTrials.gov. https://www.clinicaltrials.gov/ct2/show/NCT02491268?term=NCT02491268&amp... . Accessed 2 June 2020
    1. Abbatecola AM, Bo M, Barbagallo M, Incalzi RA, Pilotto A, Bellelli G, Maggi S, Paolisso G (2015) Severe hypoglycemia is associated with antidiabetic oral treatment compared with insulin analogs in nursing home patients with type 2 diabetes and dementia: results from the DIMORA study. J Am Med Dir Assoc 16:349.e7–349.e12. https://doi.org/10.1016/j.jamda.2014.12.014 - DOI
    1. Alzheimer's Association Report (2020) 2020 Alzheimer's disease facts and figures. Alzheimers Dement 16:391–460. https://doi.org/10.1002/alz.12068 - DOI
    1. Ancelin ML, Ripoche E, Dupuy AM, Barberger-Gateau P, Auriacombe S, Rouaud O, Berr C, Carrière I, Ritchie K (2013) Sex differences in the associations between lipid levels and incident dementia. J Alzheimers Dis 34:519–528. https://doi.org/10.3233/jad-121228 - DOI - PubMed - PMC

MeSH terms

LinkOut - more resources